Compare
Trafalgar International, Inc. vs CNBX Pharmaceuticals Inc. vs Nika Pharmaceuticals, Inc vs One World Products, Inc.
| Latest fiscal year | Trafalgar International, Inc. GCAN | CNBX Pharmaceuticals Inc. CNBX | Nika Pharmaceuticals, Inc NIKA | One World Products, Inc. OWPCLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-08-31 | 2025-12-31 | 2024-12-31 |
| Revenue | n/a | $0 | n/a | $4.9K |
| Revenue growth (YoY) | n/a | -100.0% | n/a | -35.9% |
| Gross margin | n/a | n/a | n/a | 80.5% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$331.6K | -$314.0K | -$76.4K | -$3.94M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | -$0.04 |
| Operating cash flow | -$60.2K | -$171.3K | -$79.7K | -$1.12M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | n/a | $15.1K | $1.9K | n/a |
| Total assets | $815 | $18.4K | $21.0K | $68.3K |
| Total liabilities | $742.5K | n/a | $318.6K | $5.26M |
| Shareholders' equity | -$741.6K | -$2.50M | -$297.6K | -$9.91M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 944.9K | 553.96M | 1.05B | 108.53M |
Revenue, most recent five fiscal years
| Fiscal year | Trafalgar International, Inc. | CNBX Pharmaceuticals Inc. | Nika Pharmaceuticals, Inc | One World Products, Inc. |
|---|---|---|---|---|
| Latest | $12.6K Ended 2021-12-31 | $0 Ended 2025-08-31 | $0 Ended 2024-12-31 | $4.9K Ended 2024-12-31 |
| 1 year earlier | $48.0K Ended 2020-12-31 | $130.1K Ended 2024-08-31 | $0 Ended 2023-12-31 | $7.6K Ended 2023-12-31 |
| 2 years earlier | $7.1K Ended 2019-12-31 | $410.2K Ended 2023-08-31 | $0 Ended 2022-12-31 | $125.7K Ended 2022-12-31 |
| 3 years earlier | $95.4K Ended 2018-12-31 | $30.0K Ended 2022-08-31 | $0 Ended 2021-12-31 | $38.3K Ended 2021-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-08-31 | n/a | $59.6K Ended 2020-12-31 |